Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
76 shown of 2,401 total abstracts
  1. Abstract 18682026-09-02 · 20:15 CT · E450
    MONARCH-551: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Tolaney, J. Cortes, C. Robert · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  2. Abstract 19342026-09-05 · 19:45 CT · Hall B1
    Quality of life outcomes with Trodelvy in patients with TNBC
    M. Krop, P. Schmid, A. Spira, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 16302026-09-05 · 18:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-406 study)
    J. Brahmer, M. Krop, S. Tolaney, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  4. Abstract 17032026-09-02 · 16:00 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    H. Rugo, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  5. Abstract 12602026-09-02 · 16:15 CT · Hall B1
    Long-term follow-up of Enhertu 1L for HR+ breast cancer: DESTINY-Breast-953
    T. Mok, R. Herbst · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 13792026-09-03 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-575
    N. Rizvi, G. Curigliano, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 15972026-09-02 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-462 study)
    H. Rugo, E. Winer, M. Reck, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 15892026-09-02 · 19:15 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-510
    S. Tolaney, S. Peters, F. Andre, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 18282026-09-04 · 20:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-826 study)
    M. Krop, M. Reck, C. Saura, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  10. Abstract 16282026-09-05 · 16:45 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-834 study)
    J. Brahmer, S. Antonia · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 13062026-09-03 · 18:30 CT · S100A
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M. Krop, H. Rugo, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  12. Abstract 12412026-09-01 · 20:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-71
    S. Antonia, H. Borghaei, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  13. Abstract 14912026-09-05 · 13:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-181 study)
    F. Andre, N. Rizvi, C. Robert, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 17952026-09-02 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-485 study)
    A. Spira, H. Rugo, R. Herbst, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  15. Abstract 17622026-09-02 · 18:15 CT · Hall B1
    ASCENT-778: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    M.C. Garassino, P. Schmid, C. Saura · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  16. Abstract 12162026-09-03 · 21:45 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-906 study)
    J. Brahmer, M. Reck, S. Modi, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 16012026-09-01 · 16:45 CT · S406
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    R. Herbst, S. Tolaney · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  18. Abstract 12092026-09-02 · 20:45 CT · Arie Crown Theater
    DESTINY-Breast-321: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    S. Peters, G. Curigliano, C. Saura, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  19. Abstract 12622026-09-03 · 20:45 CT · S406
    ASCENT-570: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    L. Paz-Ares, M. Reck, H. Rugo, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 17532026-09-02 · 21:45 CT · Arie Crown Theater
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    L. Paz-Ares, E. Winer, S. Tolaney · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  21. Abstract 11452026-09-04 · 15:15 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    T. Mok, C. Saura, M.C. Garassino · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 11952026-09-04 · 18:30 CT · Hall B1
    PALOMA-123: Ibrance (palbociclib) maintenance in HR+ breast cancer
    T. Mok, J. Cortes, R. Herbst, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  23. Abstract 14042026-09-03 · 18:15 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-141
    P. Schmid, S. Modi, M.C. Garassino · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 14202026-09-01 · 20:15 CT · Hall B1
    PALOMA-793: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    S. Antonia, P. Schmid, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 12862026-09-01 · 14:15 CT · Arie Crown Theater
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    C. Robert, S. Tolaney, M. Reck, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  26. Abstract 13152026-09-02 · 16:45 CT · S100A
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-380
    N. Rizvi, M. Krop, J. Cortes · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 10282026-09-05 · 18:00 CT · S406
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-744
    H. Rugo, R. Herbst, S. Tolaney, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  28. Abstract 17132026-09-05 · 20:30 CT · S100A
    MONALEESA-451: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    H. Rugo, P. Schmid, C. Saura · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  29. Abstract 12062026-09-03 · 15:30 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    H. Borghaei, J. Cortes, M. Krop · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  30. Abstract 15502026-09-04 · 16:00 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-135
    R. Herbst, P. Schmid, N. Rizvi, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 10572026-09-02 · 15:15 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-261
    P. Schmid, G. Curigliano, T. Mok · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  32. Abstract 16832026-09-04 · 16:30 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-678
    S. Antonia, M.C. Garassino, M. Krop, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 19242026-09-01 · 14:45 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-355 study)
    A. Spira, S. Modi, T. Mok, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 11392026-09-03 · 16:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-270
    R. Herbst, H. Borghaei, L. Paz-Ares, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  35. Abstract 16312026-09-03 · 18:00 CT · E450
    Long-term follow-up of Enhertu 1L for HR+ breast cancer: DESTINY-Breast-815
    L. Paz-Ares, T. Mok · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  36. Abstract 16312026-09-05 · 16:15 CT · S406
    Long-term follow-up of Enhertu maintenance for HR+ breast cancer: DESTINY-Breast-509
    H. Rugo, C. Robert, S. Peters, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  37. Abstract 13612026-09-02 · 15:00 CT · E450
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-456
    F. Andre, R. Herbst, N. Rizvi · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  38. Abstract 16902026-09-03 · 20:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-304 study)
    M. Krop, M. Reck, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 11022026-09-02 · 20:30 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-164
    C. Saura, J. Cortes · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  40. Abstract 11512026-09-03 · 19:00 CT · Arie Crown Theater
    KEYNOTE-830: Keytruda (pembrolizumab) 3L+ in TNBC
    S. Antonia, J. Cortes, J. Brahmer, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  41. Abstract 14082026-09-04 · 14:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-241
    M. Krop, P. Schmid, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  42. Abstract 11952026-09-05 · 21:00 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-394
    J. Brahmer, G. Curigliano, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  43. Abstract 16772026-09-03 · 21:30 CT · E450
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    G. Curigliano, E. Winer · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  44. Abstract 12872026-09-03 · 21:00 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    J. Brahmer, E. Winer, F. Andre, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 12572026-09-05 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-342 study)
    N. Rizvi, H. Borghaei, P. Schmid, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 12652026-09-03 · 18:30 CT · Hall B1
    MONARCH-294: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    C. Saura, S. Tolaney, E. Winer · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 17732026-09-04 · 19:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-469
    F. Andre, S. Tolaney, E. Winer, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  48. Abstract 16772026-09-03 · 16:45 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    J. Brahmer, M. Krop, P. Schmid, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  49. Abstract 12502026-09-01 · 21:30 CT · S100A
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-64
    A. Spira, S. Modi, S. Peters, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  50. Abstract 14532026-09-03 · 13:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-116 study)
    J. Brahmer, C. Saura · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract 18232026-09-05 · 14:30 CT · E450
    Long-term follow-up of Trodelvy 1L for TNBC: ASCENT-99
    E. Winer, L. Paz-Ares, S. Antonia, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 14912026-09-02 · 19:45 CT · S100A
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-865
    C. Robert, H. Rugo, C. Saura, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 15942026-09-05 · 15:45 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-360 study)
    M.C. Garassino, N. Rizvi · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 19372026-09-02 · 20:00 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    L. Paz-Ares, S. Peters, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  55. Abstract 14432026-09-02 · 15:15 CT · E450
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-187
    H. Borghaei, S. Tolaney, A. Spira · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  56. Abstract 15822026-09-02 · 19:30 CT · S406
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-709 study)
    A. Spira, N. Rizvi · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  57. Abstract 11662026-09-05 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-497 study)
    C. Robert, L. Paz-Ares, M.C. Garassino, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 15572026-09-04 · 13:15 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-862
    J. Cortes, C. Robert · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  59. Abstract 10022026-09-03 · 18:00 CT · S406
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-850
    J. Brahmer, C. Robert · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 17892026-09-04 · 15:30 CT · S100A
    Long-term follow-up of Tecentriq 3L+ for TNBC: IMpower-506
    S. Peters, E. Winer, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 12352026-09-04 · 18:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-500 study)
    J. Brahmer, N. Rizvi, T. Mok, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  62. Abstract 11322026-09-03 · 20:45 CT · S100A
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-879
    S. Modi, P. Schmid, S. Peters, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 17932026-09-04 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-604
    S. Peters, N. Rizvi, H. Borghaei, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract 14862026-09-05 · 20:30 CT · S100A
    KEYNOTE-404: Keytruda (pembrolizumab) 1L in TNBC
    S. Peters, C. Saura, S. Antonia · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 14552026-09-02 · 13:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-325
    R. Herbst, T. Mok, S. Tolaney · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 12012026-09-05 · 18:45 CT · E450
    Long-term follow-up of Enhertu 3L+ for HR+ breast cancer: DESTINY-Breast-421
    M. Krop, J. Cortes, R. Herbst, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  67. Abstract 16062026-09-04 · 14:45 CT · S406
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-167
    F. Andre, A. Spira, S. Peters, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 13052026-09-01 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-570 study)
    H. Rugo, M. Krop · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  69. Abstract 16202026-09-02 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-622
    A. Spira, T. Mok, H. Rugo, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  70. Abstract 18602026-09-03 · 20:15 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    P. Schmid, C. Robert, F. Andre · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  71. Abstract 15822026-09-02 · 16:45 CT · E450
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-379
    M. Krop, R. Herbst · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  72. Abstract 12402026-09-04 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-476 study)
    M.C. Garassino, P. Schmid, H. Borghaei, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 17282026-09-02 · 21:30 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with TNBC
    E. Winer, M.C. Garassino, T. Mok, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  74. Abstract 10692026-09-01 · 20:15 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-599
    C. Saura, J. Cortes, A. Spira · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  75. Abstract 13822026-09-03 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-428 study)
    R. Herbst, H. Borghaei, F. Andre, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  76. Abstract 16672026-09-05 · 14:00 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-575
    N. Rizvi, T. Mok, S. Antonia, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.